ぶどう膜炎(Uveitis)：世界の治験レビュー（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Uveitis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Uveitis to Ophthalmology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Uveitis to Ophthalmology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Uveitis 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Uveitis Therapeutics Clinical Trials 31
Prominent Drugs 32
Latest Clinical Trials News on Uveitis 33
May 05, 2015: Abbvie Announces Pivotal Phase 3 Data Evaluating Efficacy And Safety Of Humira (Adalimumab) In Patients With Non-Infectious Intermediate, Posterior, Or Panuveiti 33
May 05, 2015: Kineta Announces Promising Top-line Clinical Results for Dalazatide; Target Implicated in Broad Array of Autoimmune Diseases 33
Apr 30, 2015: Clearside Biomedical to Report Efficacy and Safety Results in Non-infectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide at 2015 ARVO Meeting 35
Mar 16, 2015: Clearside Biomedical Reports Efficacy and Safety Results in Non-infectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide 35
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
Novartis AG 36
Clinical Trial Overview of Novartis AG 36
XOMA Corporation 38
Clinical Trial Overview of XOMA Corporation 38
Valeant Pharmaceuticals International, Inc. 39
Clinical Trial Overview of Valeant Pharmaceuticals International, Inc. 39
F. Hoffmann-La Roche Ltd. 40
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 40
Actavis plc 41
Clinical Trial Overview of Actavis plc 41
Les Laboratoires Servier SAS 42
Clinical Trial Overview of Les Laboratoires Servier SAS 42
AbbVie Inc. 43
Clinical Trial Overview of AbbVie Inc. 43
Panacea Biotec Limited 44
Clinical Trial Overview of Panacea Biotec Limited 44
Lux Biosciences, Inc. 45
Clinical Trial Overview of Lux Biosciences, Inc. 45
Celgene Corporation 46
Clinical Trial Overview of Celgene Corporation 46
Clinical Trial Overview of Top Institutes / Government 47
National Eye Institute 47
Clinical Trial Overview of National Eye Institute 47
Moorfields Eye Hospital NHS Foundation Trust 49
Clinical Trial Overview of Moorfields Eye Hospital NHS Foundation Trust 49
Oregon Health & Science University 50
Clinical Trial Overview of Oregon Health & Science University 50
The Johns Hopkins University 51
Clinical Trial Overview of The Johns Hopkins University 51
University of California, San Francisco 52
Clinical Trial Overview of University of California, San Francisco 52
Capital Medical University 53
Clinical Trial Overview of Capital Medical University 53
Duke University 54
Clinical Trial Overview of Duke University 54
Institut de Recherches Internationales Servier 55
Clinical Trial Overview of Institut de Recherches Internationales Servier 55
JHSPH Center for Clinical Trials 56
Clinical Trial Overview of JHSPH Center for Clinical Trials 56
Rafik Hariri University Hospital 57
Clinical Trial Overview of Rafik Hariri University Hospital 57
Five Key Clinical Profiles 58
Appendix 98
Abbreviations 98
Definitions 98
Research Methodology 99
Secondary Research 99
About GlobalData 100
Contact Us 100
Disclaimer 100
Source 100